The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
 
Robert William Lentz
No Relationships to Disclose
 
Tyler Friedrich
No Relationships to Disclose
 
Junxiao Hu
No Relationships to Disclose
 
Alexis Diane Leal
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
Sunnie S. Kim
Consulting or Advisory Role - Daiichi Sankyo/Lilly
 
S. Lindsey Davis
Honoraria - Bristol-Myers Squibb; Incyte; OncLive
Speakers' Bureau - Allergan (I); Teva (I)
Research Funding - AstraZeneca (Inst); Boston Scientific (I); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Merck (Inst); OncoMed (Inst); Roche (Inst); Senhwa Biosciences (Inst)
 
Tom Purcell
No Relationships to Disclose
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); QED Therapeutics
Research Funding - Alexo Therapeutics (Inst); Beigene (Inst); D3 (Inst); Immunomedics (Inst); OncoMed (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - HalioDx; Ipsen (Inst); Pfizer (Inst)
Research Funding - Merck (Inst)
Other Relationship - Immune Design